Celldex Therapeutics, Inc. — Q1 2017 Form 10-Q
Business context and period: Unaudited results for the three months ended March 31, 2017, compared with Q1 2016. Celldex is a clinical-stage biopharmaceutical company developing oncology and immunotherapy candidates; revenue primarily comes from collaborations, contracts and grants, not product sales. The company’s latest-stage candidate, glembatumumab vedotin, was in Phase 2b testing for triple-negative breast cancer.
Financial results and liquidity
| Metric | Q1 2017 | Q1 2016 / prior date |
|---|---|---|
| Revenue | $1.5 million | $1.3 million |
| Research and development expense | $25.8 million | $27.4 million |
| General and administrative expense | $7.2 million | $9.3 million |
| Operating loss | $35.1 million | $35.7 million |
| Net loss | $34.3 million | $34.7 million |
| Basic and diluted loss per share | $0.28 | $0.35 |
| Net cash used in operating activities | $35.3 million | $34.9 million |
At March 31, 2017, cash and cash equivalents were $42.5 million and marketable securities were $124.5 million, totaling approximately $167.0 million. Current assets were $173.5 million and current liabilities $27.0 million. Total liabilities were $112.2 million; no conventional borrowing or debt balance is clearly disclosed in the filing text. Liabilities include $47.6 million of Kolltan contingent consideration. The filing does not provide a gross-profit figure or a meaningful product margin.
Cash provided by investing activities was $22.4 million, mainly from net sales and maturities of marketable securities. Financing activities provided $12.9 million, including $12.8 million net proceeds from stock sales under the Cantor equity agreement. Cash and cash equivalents increased by $0.04 million during the quarter. Shares outstanding rose to 124.2 million at quarter-end from 120.5 million at year-end 2016.
Material changes versus Q1 2016
- Revenue increased $0.2 million, or 18%, largely from the BMS collaboration and Rockefeller research agreement.
- R&D expense fell $1.7 million. Lower product-development spending, including costs no longer incurred for discontinued Rintega, more than offset increased spending on glembatumumab vedotin and newer programs.
- G&A expense declined $2.1 million, mainly because of lower Rintega commercial-planning costs.
- A $3.4 million noncash loss from remeasuring Kolltan contingent consideration was recorded in Q1 2017; there was no corresponding expense in Q1 2016. This partly offset lower operating expenses.
- Net loss improved by $0.4 million, while operating cash use increased by $0.4 million, primarily due to working-capital changes, including payment of $4.7 million of assumed Kolltan vendor liabilities.
Outlook, commentary and risks
- Management said available cash, cash equivalents and marketable securities were expected to fund planned operations for at least 12 months from the financial statements’ issuance date; elsewhere, it said resources plus anticipated Cantor sales were expected to fund operations through 2018. The outlook depends on financing and whether Kolltan milestones are paid in cash.
- Management expected operating cash use to decrease over the next 12 months and R&D and G&A expenses to remain relatively consistent, subject to quarterly fluctuations. No revenue or earnings guidance was provided.
- Celldex may need additional capital through equity, debt, licensing, collaborations or business combinations. Financing may be unavailable or unfavorable; equity may dilute shareholders, and debt may add cash obligations and restrictive covenants. Insufficient funding could delay or discontinue trials or programs.
- Kolltan acquisition payments could total up to $172.5 million if specified development, regulatory or commercial milestones are achieved. Payment may be in cash, shares or both, subject to listing requirements and agreement terms. The recorded fair value rose from $44.2 million at year-end to $47.6 million at March 31, based on significant unobservable estimates.
- Clinical, regulatory, manufacturing, trial-enrollment, intellectual-property and partnership outcomes remain material uncertainties. Early-stage clinical findings may not predict later results. Management reported no material changes to previously disclosed risk factors.
- Pipeline timing: management anticipated METRIC enrollment completion by the end of September 2017 and completion of enrollment across the varlilumab/Opdivo Phase 2 cohorts in Q1 2018. These are expectations, not assurances.
- Celldex had $32.0 million of gross offering capacity remaining under its Cantor agreement at quarter-end and a $250 million shelf registration statement. Marketable securities were described as high investment grade, with no securities considered other-than-temporarily impaired.
Key facts investors should verify
- Whether cash burn and the stated runway remain consistent with the latest cash, securities, financing activity and clinical-trial spending.
- Progress and results for METRIC, the varlilumab/Opdivo cohorts, and other key trials, including whether enrollment and milestones meet management’s expected timing.
- Potential milestone achievement, fair-value changes and cash-versus-stock settlement of the Kolltan obligations, including any required shareholder approval.
- Actual use and dilution from the Cantor facility and shelf registration, and whether additional capital or partnerships are secured on acceptable terms.
- Whether the reported interim clinical signals translate into adequately powered, statistically persuasive and regulatorily sufficient results.